Impact of extended tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM)

This Plain Language Summary of publication article (PLSP) from Future Cardiology discusses findings from the ATTR-ACT study, it evaluated tafamidis as a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition. Participants took tafamidis or placebo for up to 2.5 years in the initial study. Afterward, they could join the extension study, where all participants received tafamidis for up to 5 additional years. Researchers assessed changes in participants’ quality of life and heart failure symptoms, with results from the first 2.5 years of the extension study showing the long-term impact of tafamidis.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy’ and was published in European Journal of Heart Failure.

Visit Wiley using the link to read the original article.

• Amyloidosis
• Cardiomyopathies
• heart failure
• quality of life
• transthyretin